ArticleFrontiers in immunology2026
Shenling Baizhu powder alleviates non-alcoholic steatohepatitis by reducing PPARα-mediated NLRP3 inflammasome activation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nonalcoholic steatohepatitis (NASH) is the progressive stage of nonalcoholic fatty liver disease characterized by varying degrees of inflammation, hepatic steatosis, liver cell damage and fibrosis, which can seriously harm people's health. Shenling Baizhu (SL) powder exhibits a strong capacity to modulate cellular mechanisms, thereby demonstrating exceptional potential in addressing inflammatory and oxidative stress-related pathologies. However, the exact mechanism of SL in NASH has not been fully elucidated. We aimed to explore the therapeutic effect and potential mechanism of SL in NASH mice. Methods: We fed mice the methionine-choline deficiency (MCD) diet to construct a model of NASH. The efficacy of SL in regulating the progression of NASH was evaluated by biochemical and histopathological analyses. The effects of SL on oxidative stress and inflammatory cytokines were examined. Transcriptomic analysis was performed to further explore the potential molecular mechanisms regulated by SL. Finally, the expression of key proteins was verified by Western blotting. Results: The pathological phenotype of NASH was successfully established in mice. SL intervention demonstrated significant therapeutic benefits in reducing hepatic lipid accumulation, alleviating liver fibrosis, and decreasing inflammatory responses. Additionally, SL intervention was shown to ameliorate ER stress by attenuating the unfolded protein response (UPR). Gene expression profiling coupled with pathway analysis revealed that SL exerted its effects through the modulation of critical signalling pathways, including the PPAR signalling axis. Additionally, SL inhibited NLRP3 inflammasome activation and reduced the expression of downstream inflammatory cytokines in the liver. Discussion: The findings indicate that SL mitigates NASH by activating the PPAR pathway and suppressing the ER stress-triggered UPR, thereby inhibiting NLRP3 inflammasome activation. These results highlight the therapeutic potential of SL for NASH management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.